Dual-agent PET/MR with time of flight detects more cancer
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) followed by quantitative scanning significantly improves image quality and detection of bone metastases at a lower dose, according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). {read more here}
A monoclonal antibody-based agent could prove useful for diagnosing and treating patients with pancreatic cancer, according to research presented this week at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting. {read more here}
Identifying Alzheimer’s disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. A new study demonstrates that a single dual time-point PET scan could identify important biomarkers of the disease. {read more here}
Researchers in Switzerland are setting their sights on fluoroethyl-tyrosine (FET) PET imaging as the best way to assess adult brainstem glioma and gauge patients’ chances for progression-free survival. Study results were presented on Sunday at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. {read more here}